Basroparib

DB21582InvestigationalSmall molecule

Basroparib is a small molecule drug. The usage of the INN stem '-parib' in the name indicates that Basroparib is a poly-ADP-Ribose polymerase inhibitor. Basroparib is under investigation in clinical... Basroparib is under investigation in clinical trial NCT04505839 (First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors).

Mechanism: Pharmacologically active on Poly [ADP-ribose] polymerase tankyrase-1 and Poly [ADP-ribose] polymerase tankyrase-2
Curator reviewed
Formula / weight: C₁₈H₂₁F₂N₇O₃ · 421.409 g/mol (avg)

Resolves to

Compound

UNIIP5LYN8CD74CAS1858179-75-5ChEMBLCHEMBL5095091ChEBI758675PubChem137017382

Structure

InChIKeyALDDPEMJJONRDI-UHFFFAOYSA-NSMILESCOCCOC1=CC(F)=C(N2CCN(CC2)C2=NC(=O)C3=C(N2)N(C)N=N3)C(F)=C1

Targets

O95271TNKSQ9H2K2TNKS2

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Basroparib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account